Clinical Trials Logo

Demoralization clinical trials

View clinical trials related to Demoralization.

Filter by:
  • None
  • Page 1

NCT ID: NCT05883540 Recruiting - Depression Clinical Trials

Lysergic Acid Diethylamide (LSD) in Palliative Care

LPC
Start date: June 11, 2024
Phase: Phase 2
Study type: Interventional

Background: Terminally ill patients often experience significant psychosocial distress having depressed mood, death anxiety, pain, and an overall poor quality of life. Recent evidence from pilot studies suggests that serotonergic hallucinogens including lysergic acid diethylamide (LSD) and psilocybin produce significant and sustained reductions of depressive symptoms and anxiety, along with increases in quality of life, and life meaning in patients suffering from life-threatening diseases. Additionally, serotonergic hallucinogens may produce antinociceptive effects. Objective and Design: The study aims to evaluate effects of LSD on psychosocial distress in 60 patients suffering from an end-stage fatal disease with a life expectancy ≥12wks and ≤2yrs in an active placebo-controlled double-blind parallel study. Patients will be allocated in a 2:1 ratio to one of the two intervention arms receiving either two moderate to high doses of LSD (100 µg and 100 µg or 100 µg and 200 µg) as intervention and two low doses of LSD (25 µg and 25 µg) as active-placebo control.

NCT ID: NCT05841459 Completed - Demoralization Clinical Trials

Spiritual Well-being, Self-compassion, Physical Symptoms Distress and Demoralization Among HD Patients

Start date: February 1, 2023
Phase:
Study type: Observational

To explore the associations between spiritual well-being, self-compassion, physical symptoms distress and demoralization among hemodialysis patients

NCT ID: NCT05403086 Not yet recruiting - Demoralization Clinical Trials

Pragmatic Trial of Psilocybin Therapy in Palliative Care

PT2PC
Start date: August 15, 2024
Phase: Phase 2
Study type: Interventional

This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).

NCT ID: NCT05227742 Recruiting - Demoralization Clinical Trials

Exploratory Study of Low Dose Psilocybin

Start date: August 15, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of the present study is to evaluate the feasibility, initial signals of efficacy, and potential mechanisms of action of "microdoses" of psilocybin (i.e., low doses of psilocybin that are not believed to produce mystical-type, transcendent, hallucinogenic, or other overtly salient subjective effects that limit functionality) in the treatment of moderate to severe demoralization (feelings of hopelessness and meaningless that frequently accompany medical illness and other life hardship).

NCT ID: NCT04950608 Active, not recruiting - Clinical trials for Cancer-related Problem/Condition

Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care

PATH
Start date: March 9, 2022
Phase: Phase 2
Study type: Interventional

The overall objective of this study is to develop and pilot test a novel regimen of psilocybin-assisted psychotherapy for demoralization in patients receiving hospice care. -The name of the study drug involved in this study is Psilocybin

NCT ID: NCT04006327 Completed - Demoralization Clinical Trials

Demoralization Among Palliative Care Patients and Their Family Caregivers in Hong Kong: A Pilot Study

Start date: November 26, 2018
Phase:
Study type: Observational

This study aims to explore the prevalence of demoralization among palliative care patients and family caregivers in Hong Kong and examines psychosocial factors associated with demoralization. We hypothesized that higher depression, caregiving strain and caregiver support needs would lead to higher demoralization, and greater perceived family support was associated with lower demoralization among patients and family caregivers.